撒哈拉以南非洲2010至2020年临床试验注册趋势:三大注册库横断面综述
该横断面研究检索ClinicalTrials.gov、PACTR和ISRCTN三个注册库,描述2010年1月至2020年7月撒哈拉以南非洲临床试验注册特征。CTG注册量最高(2622项),其次PACTR(1501项)和ISRCTN(507项),注册量2018-2019年达峰后近期下降。随机对照试验占至少80%,药物三期试验以感染/寄生虫病为主。完成试验结果发布率ISRCTN为58%、CTG为16.5%,提示报告偏倚。
要点
- 撒哈拉以南非洲临床试验注册量2010年起渐增,2018-2019年达峰后近期下降。
- 随机对照试验在三大注册库中均占至少80%,药物三期试验多针对感染/寄生虫病。
- 完成试验结果发布率ISRCTN为58%、CTG为16.5%,提示报告偏倚。
核心结论
- 尽管2010至2020年撒哈拉以南非洲临床试验注册量逐渐增加,但近期趋势显示该区域注册试验数量下降。
- 加强国家和区域监管能力将改善临床试验注册并减少已完成试验的报告偏倚。
研究设计与样本
- 横断面研究设计,描述2010年1月1日至2020年7月31日撒哈拉以南非洲开展的临床试验类型。
- 检索ClinicalTrials.gov(CTG)、泛非临床试验注册库(PACTR)和国际标准随机对照试验编号(ISRCTN)三个注册库。
- 数据提取至Excel并导入STATA进行描述性分析。
主要发现
- CTG注册试验数最高,为2622项;PACTR为1501项;ISRCTN为507项。
- 试验注册量从2010年逐渐增加,在2018-2019年达到峰值。
- 随机对照试验是最常见类型,在三个注册库中均至少占80%。
- 研究药物针对感染/寄生虫病的三期试验占多数。
- 完成试验的结果发布率:ISRCTN为58%,CTG为16.5%,提示报告偏倚。
临床怎么用
- 提示撒哈拉以南非洲临床试验注册存在报告偏倚,临床解读该区域试验证据时需考虑结果发布不完整的影响。
- 强调加强国家和区域监管能力对改善临床试验注册和减少报告偏倚的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prospective registration of clinical trials is an ethical, scientific, and legal requirement that serves several functions, including minimising research wastage and publication bias. Sub-Saharan Africa (SSA) is increasingly hosting clinical trials over the past few years, and there is limited literature on trends in clinical trial registration and reporting in SSA. Therefore, we set out to determine the trends in clinical trials registered in SSA countries between 2010 and July 2020. METHODS: A cross-sectional study design was used to describe the type of clinical trials that are conducted in SSA from 1 January 2010 to 31 July 2020. The registries searched were ClinicalTrials.gov (CTG), the Pan African Clinical Trials Register (PACTR), and the International Standard Randomized Controlled Trial Number (ISRCTN). Data were extracted into Excel and imported into STATA for descriptive analysis. RESULTS: CTG had the highest number of registered trials at 2622, followed by PACTR with 1501 and ISRCTN with 507 trials. Trials were observed to increase gradually from 2010 and peaked at 2018-2019. Randomised trials were the commonest type, accounting for at least 80% across the three registries. Phase three trials investigating drugs targeted at infections/infestations were the majority. Few completed trials had their results posted: 58% in ISRCTN and 16.5% in CTG, thus suggesting reporting bias. CONCLUSION: Despite the gradual increase in clinical trials registered during the period, recent trends suggest a drop in the number of trials registered across the region. Strengthening national and regional regulatory capacity will improve clinical trial registration and minimise reporting bias in completed clinical trials.
引用
- Edem B, Onwuchekwa C, Wariri O, et al. Trends in clinical trial registration in sub-Saharan Africa between 2010 and 2020: a cross-sectional review of three clinical trial registries. Trials. 2021. PMID: 34289892. doi:10.1186/s13063-021-05423-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。